Evicenter
MarkdownMedical informationP&T meetings
Emcitate (tiratricol)

MCT8 deficiency

Last updated
81 sources

Section 4 of 6

Clinical evidence

234 evidence topics · 25 sources

Study summaries

Triac trial I

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using serum t3 concentration as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Screened, enrolled, and analyzed populations
PopulationParticipants
Screened and eligible“50”View highlighted excerpt for this quote
Declined participation“four (8%)”View highlighted excerpt for this quote
Enrolled“46 (92%)”View highlighted excerpt for this quote
Primary endpoint analysis“45 (98%)”View highlighted excerpt for this quote
Completed the 12-month intervention period; secondary and exploratory endpoint analyses“40 (87%)”View highlighted excerpt for this quote
Treatment extension period“Ten (22%)”View highlighted excerpt for this quote
Description of analysis sets
Results
Participant disposition
Enrollment and withdrawals

“Between Oct 15, 2014, and June 1, 2017, we screened 50 patients, all of whom were eligible. Of these patients, four (8%) patients decided not to participate because of travel commitments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of these 50 patients, four declined to participate; 46 patients were therefore enrolled and assigned to receive Triac (appendix p 5), but one (2%) patient was withdrawn before the first control visit because of non-compliance to study procedures. This patient was included in safety analyses, but not primary efficacy analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Five of these patients did not complete the study intervention: two were withdrawn due to parental choice (one because of travel time to the study centre, one because of severe comorbidity [severe epileptic seizures and hydrocephalus]), one was lost to follow-up, one developed Graves’ disease, and one patient died from sepsis. 40 (87%) patients completed the 12-month intervention period and thus were included in the analyses of secondary and exploratory endpoints. Ten (22%) patients who completed the follow-up were also included in the long-term (median 40·4 months, IQR 38·1–41·3) treatment extension period (appendix p 5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Baseline characteristics
Efficacy results
Primary and secondary outcomes, baseline to month 12
OutcomeBaseline, mean (SD)Month 12, mean (SD)Mean change (95% CI)p value
T3, nmol/L (n = 45)“4·97 (1·55)”View highlighted excerpt for this quote“1·82 (0·69)”View highlighted excerpt for this quote“–3·15 (–3·62 to –2·68)”View highlighted excerpt for this quote“<0·0001”View highlighted excerpt for this quote
TSH, mU/L (n = 45)“2·91 (1·68)”View highlighted excerpt for this quote“1·02 (1·14)”View highlighted excerpt for this quote“–1·89 (–2·39 to –1·39)”View highlighted excerpt for this quote“<0·0001”View highlighted excerpt for this quote
Free T4, pmol/L (n = 45)“9·5 (2·5)”View highlighted excerpt for this quote“3·4 (1·6)”View highlighted excerpt for this quote“–6·1 (–6·8 to –5·4)”View highlighted excerpt for this quote“<0·0001”View highlighted excerpt for this quote
Total T4, nmol/L (n = 45)“56·0 (13·0)”View highlighted excerpt for this quote“24·4 (9·4)”View highlighted excerpt for this quote“–31·6 (–35·2 to –28·0)”View highlighted excerpt for this quote“<0·0001”View highlighted excerpt for this quote
Reverse T3, nmol/L (n = 45)“0·12 (0·10)”View highlighted excerpt for this quote“0·04 (0·04)”View highlighted excerpt for this quote“–0·08 (–0·10 to –0·05)”View highlighted excerpt for this quote“<0·0001”View highlighted excerpt for this quote
Weight-for-age Z score (n = 40)“–2·98 (1·93)”View highlighted excerpt for this quote“–2·71 (1·79)”View highlighted excerpt for this quote“0·27 (0·03 to 0·50)”View highlighted excerpt for this quote“0·025”View highlighted excerpt for this quote
Resting heart rate, bpm (n = 34)“112 (23)”View highlighted excerpt for this quote“104 (17)”View highlighted excerpt for this quote“–9 (–16 to –2)”View highlighted excerpt for this quote“0·010”View highlighted excerpt for this quote
Mean heart rate over 24 h, bpm (n = 31)“102 (14)”View highlighted excerpt for this quote“97 (9)”View highlighted excerpt for this quote“–5 (–9 to –1)”View highlighted excerpt for this quote“0·012”View highlighted excerpt for this quote
Systolic blood pressure, mm Hg (n = 32)“108 (8)”View highlighted excerpt for this quote“102 (10)”View highlighted excerpt for this quote“–5 (–9 to –1)”View highlighted excerpt for this quote“0·0086”View highlighted excerpt for this quote
Systolic blood pressure, percentile (n = 32)“78 (24)”View highlighted excerpt for this quote“61 (29)”View highlighted excerpt for this quote“–18 (–29 to –6)”View highlighted excerpt for this quote“0·0037”View highlighted excerpt for this quote
Diastolic blood pressure, mm Hg (n = 32)“64 (9)”View highlighted excerpt for this quote“62 (9)”View highlighted excerpt for this quote“–2 (–6 to –2)”View highlighted excerpt for this quote“0·35”View highlighted excerpt for this quote
Sex hormone-binding globulin, nmol/L (n = 39)“212 (91)”View highlighted excerpt for this quote“178 (76)”View highlighted excerpt for this quote“–35 (–55 to –15)”View highlighted excerpt for this quote“0·0013”View highlighted excerpt for this quote
Total cholesterol, mmol/L (n = 40)“3·2 (0·7)”View highlighted excerpt for this quote“3·4 (0·7)”View highlighted excerpt for this quote“0·2 (0·0 to 0·3)”View highlighted excerpt for this quote“0·056”View highlighted excerpt for this quote
Creatine kinase, U/L (n = 40)“108 (90)”View highlighted excerpt for this quote“161 (117)”View highlighted excerpt for this quote“53 (27 to 78)”View highlighted excerpt for this quote“<0·0001”View highlighted excerpt for this quote
Secondary endpoints: bodyweight, heart rate, blood pressure, and tissue markers

“We assessed the secondary endpoints in the 40 patients who completed the 12-month treatment. We identified a significant increase in weight-for-age Z score at month 12 (0·27 SDs, 95% CI 0·03–0·50; p=0·0253; figure 1; table 2; appendix p 8), equating to a mean increase in body weight of 2·7 kg (1·9–3·5; p<0·0001); by contrast, in untreated patients, the bodyweight-for-age Z score has been shown to progressively reduce over time (appendix p 8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Between baseline and month 12, resting heart rate, as measured by electrocardiography, decreased by 9 bpm (95% CI 2–16; p=0·010), and mean heart rate, as measured by 24-h cardiac monitoring, decreased by 5 bpm (1–9; p=0·012; appendix p 9). Mean systolic blood pressure decreased over the 12-month study from the 78th percentile to the 61th percentile, equating to a change of 18 percentile points (95% CI 6–29; p=0·0037; table 2). The proportion of patients with systolic hypertension decreased from 34% (n=12/35) at baseline to 9% (n=3/32 at month 12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The serum concentrations of sex hormone-binding globulin decreased by 35 nmol/L (15–55; p=0·0013). However, mean serum total cholesterol concentration did not significantly change between baseline and month 12 (difference 0·2, 95% CI 0·0–0·3; p=0·056). Finally, serum creatine kinase concentrations increased by 53 U/L (27–78; p<0·0001) by month 12 (table 2; appendix p 10).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Health-related quality of life and patient-reported outcomes
Safety results
Adverse events in more than 10% of participants, serious events, and severity
Adverse eventParticipants with at least one event, n (%), N = 46Number of events
Total adverse events“43 (93%)”View highlighted excerpt for this quote“150”View highlighted excerpt for this quote
Gastroenteritis“11 (24%)”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote
Nasopharyngitis“11 (24%)”View highlighted excerpt for this quote“14”View highlighted excerpt for this quote
Influenza or influenza-like illness“9 (20%)”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote
Upper-respiratory-tract infection“9 (20%)”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote
Bronchitis“6 (13%)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
Diarrhoea“5 (11%)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Vomiting“5 (11%)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Otitis media“5 (11%)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Serious adverse events“18 (39%)”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote
Fatal adverse events“1 (2%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Adverse events leading to premature treatment discontinuation (autoimmune thyroid disorder)“1 (2%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Severe adverse events“4 (9%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote
Moderate adverse events“4 (9%)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Mild adverse events“40 (87%)”View highlighted excerpt for this quote“141”View highlighted excerpt for this quote
Probable relation to the study drug“6 (13%)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote
Prescribing information: Study 2 adverse reactions
Adverse reactionStudy 2, EMCITATE, N = 46, n (%)
Diarrhea“6 (13)”
Vomiting“5 (11)”
Rash“4 (9)”
Hyperhidrosis“3 (7)”
Study limitations
Summary

Triac Trial I was an open-label, single-arm, phase 2 trial in which 46 participants were enrolled, 45 were included in the primary analysis, and 40 completed 12 months of treatment. The investigators state that the absence of a control group and the open-label design do not allow causality to be proven, that the sample size did not allow control for factors other than the intervention, that few adults were enrolled, and that missing measurements and withdrawals may have caused selection bias. The trial was not designed to assess neurodevelopment. The G-BA did not identify validated evidence linking a given change in serum T3 to individual symptoms, found no significant change in bodyweight or height z-scores against a WHO reference population, did not use the neurocognitive endpoints because fewer than 70% of assessments were returned, noted that no quality-of-life endpoints were collected, and could not rule out under-assessment of severe adverse events. The caregiver-reported outcomes come from a post-hoc analysis of an open-label trial.

Limitations stated by the investigators

“Inherent to studies in such a heterogeneous population, the effect size of outcomes varied within the study cohort, suggesting inter-individual variation in degree of benefit between patients. The small sample size did not allow identification or statistical control for factors other than the intervention that might modulate treatment effects. Another limitation was the small number of adult patients enrolled in the study, as a consequence of high mortality during childhood. Moreover, the low physical and cognitive abilities of the participants, a feature that is inherent to the disorder, precluded recording some study parameters in all patients. Together with study withdrawals, this issue might have, unavoidably, caused selection bias in the data used for statistical analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although our study design, including the absence of a control group and open-label design, does not enable us to prove causality, the observed unidirectional changes in serum T3 concentrations can likely be attributed to Triac treatment, given the substantial evidence from preclinical and clinical studies on the effects of Triac” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Our trial was not designed to detect whether Triac also modulates neurodevelopment in human MCT8 deficiency, since the study did not include specific neurodevelopmental outcomes and enrolled patients of all ages. Therefore, most patients studied would have passed the small window of opportunity to modulate brain development.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

ReTRIACt

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using serum t3 rate of change as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Prescribing information: analysis set and model
Analysis elementQuoted record
Analysis set for both primary endpoints“Full Analysis Set”
Model for primary endpoint 1“Estimates from random effects model”
Results
Participant disposition
Baseline characteristics
Efficacy results
Primary endpoints in SI units, observed-case rescue analysis, and reinitiation
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Prescribing information: Study 1 adverse reactions
Adverse reactionStudy 1, EMCITATE, N = 20, n (%)
Diarrhea“0”
Vomiting“2 (10)”
Rash“2 (10)”
Hyperhidrosis“1 (5)”
Study limitations
Summary

ReTRIACt enrolled 20 participants and randomized 15 of them (eight to placebo withdrawal, seven to continued tiratricol); in 2024 the manufacturer described the planned study as including 16 evaluable participants. The study was closed at the FDA's recommendation, and the analysis plan was revised to add the T3 rate-of-change endpoint (primary endpoint 1) before that endpoint was reported. Primary endpoint 1 met its significance criterion (ratio 1.5, 95% CI 1.0 to 2.2; p=0.034). For the rescue endpoint (primary endpoint 2), the difference in proportions was 0.36 with a 95% CI of -0.16 to 0.77 (p=0.182); one discontinuation in the tiratricol group for non-medical family reasons was counted as rescue, and the observed-case comparison was 4 versus 0 (p=0.070). The randomized period lasted at most 30 days and evaluated withdrawal after stable maintenance treatment; it did not evaluate treatment initiation or long-term clinical outcomes. The prescribing information reports adverse reactions for all 20 enrolled participants and does not report them by randomized arm. The congress report lists six serious adverse events in four participants and one death from aspiration pneumonia, none considered treatment-related. Enrolled participants were aged 5 to 31 years, so the study did not include infants.

Triac trial II

Objective
Location and study date
Registry dates and enrollment
FieldQuoted record
Study start (actual)“2020-12-07”
Primary completion (estimated)“2027-07-18”
Study completion (estimated)“2027-08-18”
Recruitment status“Active, not recruiting”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using GMFM-88 total score as a co-primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Overview of treatment-emergent adverse events in Part I
Event categoryParticipants, N=22, n (%)Events
Any treatment-emergent adverse event (TEAE)“21 (95.5)”“208”
Any TEAE at least possibly related to study treatment“13 (59.1)”“20”
Any TEAE leading to discontinuation of study treatment“0”“0”
Any TEAE of CTC Grade 3 or higher“13 (59.1)”“19”
Any serious treatment-emergent adverse event (SAE)“10 (45.5)”“26”
Any SAE at least possibly related to study treatment“1 (4.5)”“2”
Any SAE leading to death“0”“0”
Study limitations
Summary

Triac Trial II was a single-arm, open-label phase 2 trial that enrolled 22 participants aged 5 to 28 months (median 16 months), of whom 21 completed 96 weeks. Neurodevelopmental outcomes were compared with historical scores from untreated participants in Triac Trial I; the co-primary endpoints were not met (GMFM-88 mean difference -2.42; BSID-III gross motor mean difference 0.21). The absence of a concurrent control group limits the separation of treatment effect from expected development, and the post-hoc improvements in other domains were not pre-specified. Only two participants were younger than 6 months at baseline. The trial targeted serum T3 at or below the lower limit of normal with a mean dose of 175 mcg/kg, compared with 37 mcg/kg in Triac Trial I; the EMA assessment reported increases in systolic blood pressure and markers of bone loss at these doses, and the G-BA excluded the trial from the German benefit assessment because its titration targets differed from the product information. Serious adverse events occurred in 10 of 22 participants (45.5%). The results summarized here come from a regulatory assessment, a manufacturer topline report, a registry record, and a 2026 congress abstract.

EMC cohort study

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using serum t3 concentration as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline cohort characteristics
CharacteristicOff-label use cohort, n = 67
Age, median (range), years“4.6 (0.5-66.8)”View highlighted excerpt for this quote
Age 2.5 years or younger, n (%)“23 (34%)”View highlighted excerpt for this quote
Age older than 2.5 to 5 years, n (%)“13 (19%)”View highlighted excerpt for this quote
Age older than 5 to 10 years, n (%)“17 (25%)”View highlighted excerpt for this quote
Age older than 10 to 18 years, n (%)“10 (15%)”View highlighted excerpt for this quote
Age older than 18 years, n (%)“4 (6%)”View highlighted excerpt for this quote
Male, n (%)“67 (100%)”View highlighted excerpt for this quote
Continent of origin: Europe, n (%)“45 (67%)”View highlighted excerpt for this quote
Continent of origin: Asia, n (%)“10 (15%)”View highlighted excerpt for this quote
Continent of origin: Oceania, n (%)“5 (7%)”View highlighted excerpt for this quote
Continent of origin: North America, n (%)“4 (6%)”View highlighted excerpt for this quote
Continent of origin: South America, n (%)“2 (3%)”View highlighted excerpt for this quote
Continent of origin: Africa, n (%)“1 (1%)”View highlighted excerpt for this quote
Continuation after Triac Trial I, n (%)“27 (40%)”View highlighted excerpt for this quote
Direct off-label use, n (%)“40 (60%)”View highlighted excerpt for this quote
Serum T3, mean (SD), nmol/L“4.58 (1.11)”View highlighted excerpt for this quote
Body-weight-for-age Z-score, mean (SD)“-2.80 (1.91)”View highlighted excerpt for this quote
Tachycardia, n (%)“21 (35%)”View highlighted excerpt for this quote
Efficacy results
Changes from baseline to last visit in predefined outcomes
OutcomeBaseline, mean (SD)Last visit, mean (SD)Mean change (95% CI)P value
T3, nmol/L (n = 67)“4.58 (1.11)”View highlighted excerpt for this quote“1.66 (0.69)”View highlighted excerpt for this quote“−2.92 (−3.23 to −2.61)”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Weight-for-age Z-score (n = 58)“−2.81 (1.94)”View highlighted excerpt for this quote“−2.64 (1.81)”View highlighted excerpt for this quote“0.17 (−0.18 to 0.53)”View highlighted excerpt for this quote“0.3263”View highlighted excerpt for this quote
Weight-for-age Z-score minus predicted weight-for-age Z-score (n = 55)“0.07 (1.83)”View highlighted excerpt for this quote“0.79 (1.92)”View highlighted excerpt for this quote“0.72 (0.36 to 1.09)”View highlighted excerpt for this quote“0.0002”View highlighted excerpt for this quote
Height-for-age Z-score (n = 44)“−1.84 (1.77)”View highlighted excerpt for this quote“−1.92 (1.51)”View highlighted excerpt for this quote“−0.09 (−0.50 to 0.32)”View highlighted excerpt for this quote“0.6705”View highlighted excerpt for this quote
Height-for-age Z-score minus predicted height-for-age Z-score (n = 43)“−0.44 (1.38)”View highlighted excerpt for this quote“0.14 (1.41)”View highlighted excerpt for this quote“0.58 (0.12 to 1.05)”View highlighted excerpt for this quote“0.0139”View highlighted excerpt for this quote
Weight-for-height Z-score (n = 44)“−2.02 (2.49)”View highlighted excerpt for this quote“−1.50 (2.44)”View highlighted excerpt for this quote“0.52 (−0.35 to 1.39)”View highlighted excerpt for this quote“0.2358”View highlighted excerpt for this quote
Heart rate, bpm (n = 48)“113 (21)”View highlighted excerpt for this quote“97 (20)”View highlighted excerpt for this quote“−17 (−24 to −10)”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Heart-rate-for-age Z-score (n = 48)“1.59 (0.89)”View highlighted excerpt for this quote“0.96 (1.01)”View highlighted excerpt for this quote“−0.64 (− 0.98 to −0.29)”View highlighted excerpt for this quote“0.0005”View highlighted excerpt for this quote
TSH, mU/L (n = 62)“3.32 (2.30)”View highlighted excerpt for this quote“0.95 (0.73)”View highlighted excerpt for this quote“−2.38 (−2.98 to −1.77)”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Free T4, pmol/L (n = 64)“9.5 (2.3)”View highlighted excerpt for this quote“3.4 (1.6)”View highlighted excerpt for this quote“−6.1 (−6.7 to −5.4)”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Total T4, nmol/L (n = 63)“54.2 (11.8)”View highlighted excerpt for this quote“18.1 (9.8)”View highlighted excerpt for this quote“−36.1 (−39.5 to −32.7)”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Sex hormone-binding globulin, nmol/L (n = 48)“245 (99)”View highlighted excerpt for this quote“209 (92)”View highlighted excerpt for this quote“−36 (−57 to −16)”View highlighted excerpt for this quote“0.0008”View highlighted excerpt for this quote
Creatinine, µmol/L (n = 47)“32 (11)”View highlighted excerpt for this quote“39 (13)”View highlighted excerpt for this quote“7 (6 to 9)”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Creatine kinase, U/L (n = 47)“110 (87)”View highlighted excerpt for this quote“128 (80)”View highlighted excerpt for this quote“18 (−8 to 45)”View highlighted excerpt for this quote“0.2166”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

This retrospective cohort included 67 participants treated off-label at 33 sites, of whom 27 (40%) had completed Triac Trial I; the baseline and 1-year data of those 27 participants are counted in both studies. Treatment duration ranged from 0.2 to 6.2 years, 4 participants were excluded from the secondary-outcome analyses, and missing measurements were handled by pairwise deletion and last available measurement. The change in body-weight-for-age Z-score relative to the healthy reference population was 0.17 SD (P = 0.3263), and the 0.72 SD increase was measured against a historical natural-history reference. The investigators state that the cohort may not represent all patients with MCT8 deficiency, that the real-life setting impeded optimal collection of efficacy and safety data, that care outside the designated centers could hamper adverse event reporting, and that neurodevelopmental outcomes were not collected uniformly. No concurrent comparator was included.

EMC survival study

Objective
Location and study date
Study design
Eligibility criteria
Treatment

No evidence found.

Study outcomes
Rationale for using all-cause mortality as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

The congress analysis included 228 of 484 screened participants and compared 111 treated participants with 117 untreated participants; it reported 5 versus 27 deaths over a median follow-up of 4.8 years after diagnosis. Treatment was not randomized, and the treated and untreated groups differed in the proportion residing in Western countries (78% versus 57%). The reported hazard ratio (0.28, 95% CI 0.09 to 0.91) is an observational association; the authors state that confounding and immortal time bias remain potential threats to validity and that further analyses were ongoing. Missing data were handled by multiple imputation. Later manufacturer documents describe the EMC Survival Study as including more than 600 participants, while the only quoted estimate comes from the 228-participant congress analysis. As of the second-quarter 2026 interim report, the survival data had not yet been published in a peer-reviewed journal.

Pediatric TRIAC case series

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Treatment start date and current daily dose by participant
ParticipantStart dateCurrent dose
Participant 1“Nov-2019”“22 μg/kg”
Participant 2“Jun-2020”“18 μg/kg”
Participant 3“Jan-2022”“10 μg/kg”
Participant 4“Jun-2022”“26 μg/kg”
Study outcomes
Rationale for using serum t3 concentration as a biochemical outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Included participants
PopulationParticipants
Children treated with tiratricol“4”
Description of analysis sets

No evidence found.

Results
Participant disposition
Follow-up and treatment duration by participant
ParticipantFollow-up durationTreatment duration
Participant 1“3 years and 6 months”“32 months”
Participant 2“2 years and 6 months”“22 months”
Participant 3“1 year and 1 month”“6 months”
Participant 4“7 months”“5 months”
Baseline characteristics
Efficacy results
Total T3 at diagnosis and at the last control by participant
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The series included four participants from a single hospital and did not include a concurrent control group. Treatment duration ranged from 5 to 32 months. The authors describe retrospective data collection and unequal access to developmental stimulation therapies. The observed biochemical response and absence of reported adverse reactions in four participants cannot establish comparative effectiveness, quantify uncommon harms, or separate treatment effects on development from concomitant supportive care.

Early TRIAC intervention case report

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using BSID-III composite scores as a neurodevelopmental outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition
Baseline characteristics
Efficacy results
Clinical and biochemical measures at baseline and after 12 months of treatment
MeasureBaseline (21 months of age)12 months after treatment start
Weight SDS“-2.9”“-1.8”
Resting heart rate, bpm (percentile)“150 (90th-99th)”“95 (25th)”
TSH, mIU/mL“0.8”“0.7”
Free T3, pmol/L“11.7”“7.5”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

This is one participant followed without a comparator. BSID-III composite scores remained below two SDS for age at 6 and 12 months despite attainment of individual developmental milestones. The report also describes adherence interruptions of 3 to 4 consecutive days, suspected free T3 immunoassay interference, and oral baclofen introduced at 6 months. These factors limit attribution of changes to tiratricol. The maintenance dose (1,500 mcg/day, 133 mcg/kg/day) was higher than doses previously described, and a single participant provides no estimate of adverse-event frequency.

Real-world tiratricol case report

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical response as an outcome measure

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition

No evidence found.

Baseline characteristics
Thyroid function before tiratricol (32 months of age)
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The evidence for this case is one participant described in a congress abstract without a comparator. The abstract gives the starting dose in micrograms per day and later doses in mg/kg per day, so the dose units cannot be confirmed from the abstract. Epileptic encephalopathy and antiepileptic treatment during follow-up limit attribution of psychomotor changes to tiratricol. The full case report could not be retrieved for this review.

Bioavailability/Bioequivalence study

Objective
Location and study date
Study site, sponsor, and enrollment dates
CharacteristicValue
Study participating centre“Quotient Sciences Limited”
Country of recruitment“United Kingdom”
Sponsor“Rare Thyroid Therapeutics International AB”
Protocol serial number“Sponsor code MCT8-2023-5”
Date of first enrolment“06/07/2023”
Date of final enrolment“31/08/2023”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using AUC and maximum serum concentration as the bioequivalence endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and enrolled participants
PopulationParticipants
Target sample size at registration“45”
Total final enrolment“30”
Description of analysis sets
Safety and pharmacokinetic analysis counts by treatment
TreatmentSafety analysisPharmacokinetic analysis
A: round tablet, 350 micrograms, fasted“29”“29”
B: oblong tablet, 350 micrograms, fasted“29”“28”
C: oblong tablet, 1,050 micrograms, fasted“24”“24”
D: oblong tablet, 1,050 micrograms, fed“20”“20”
E: oblong tablet, 175 micrograms, fasted“25”“25”
F: oblong tablet, 175 micrograms, fed“20”“20”
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Study limitations
Summary

This single-dose crossover study enrolled 30 healthy adult male participants aged 18 to 55 years. Its results address formulation comparability, food effects, and dose proportionality. Analysis counts ranged from 20 to 29 participants per treatment, and the congress abstract does not report participant disposition, baseline demographics, adverse-event counts, or confidence intervals for the bioequivalence comparison. The registry record states that participant-level data will not be shared. Single-dose exposure in adults provides limited information on safety during lifelong treatment in children.